Sessioni Poster

Pharmacogenetics and personalized medicine

Mercoledì 28 Ottobre 2015 / 19.00-20.00
5A case of QT prolongation during therapy with tamoxifen and trastuzumab: pharmacogenetic analysis to clarify the occurred event
Antoniazzi S., Falvella FS., Massari F., Cheli S., Clementi E., Tomirotti M., Gambini D.
46

UGT1A1 and PPARA as genetic predictors of liver abnormalities in HIV infected patients on atazanavir treatment



Cheli S., Riva A., Ricci E., Resnati C., Gervasoni C., Galli M., Clementi E., Falvella FS.
205rs489693 melanocortin receptor-4 gene polymorphism is associated with the progression-free survival of glioblastoma patients treated with concomitant radio-chemotherapy
Pasqualetti F., Orlandi P., Giuliani D., Cantarella M., Menghini V., Sechi A., Di Desidero T., Fioravanti A., Simeon V., Fabrini MG., Di Stefano AL., Sanson M., Danesi R., Guarini S., Bocci G.
217The abacavir pharmacogenetic: screening of HLA-B*57.01 allele for preventing the hypersensitivity reaction

Manzo V., Charlier B., Conti V., Izzo V., Corbi G., Russomanno G., Malangone P., Boffa N., Senatore C., Mazzeo M., Filippelli A.
232Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.
Perrone G ., Tassi R., Brugia M., Simi L., Petreni P., Mori E., Landini I ., Mazzei T., Pazzagli M ., Mini E., Nobili S.
244Potential role of long noncoding RNA GAS5 in rapamycin-induced reversion of glucocorticoid resistance
Lucafò M., Bravin V., Tommasini A., Di Silvestre A., Martelossi S., Ventura A., Decorti G., De Iudicibus S.
252miRNA regulation during glucocorticoid treatment in children with inflammatory bowel disease
De Iudicibus S., Lucafò M., Vitulo N., Zimbello R., Forcato C., Martelossi S., Di Silvestre A., Valle G., Ventura A., Decorti G.
271Effect of renal transporter genetic polymorphisms on linezolid pharmacokinetic
Allegra S., Cusato J., Baietto L., Fatiguso G., Ariaudo A., Corcione S., Di Perri G., De rOSA FG., D'Avolio A.
272Identification of cellular models to study the role of the long noncoding RNA GAS5 as modulator of glucocorticoid response
Di Silvestre A., Lucafò M., De Iudicibus S., Bravin V., Avian A., Romano M., Decorti G.
274Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir
Cusato J., De Nicolo' A., Boglione L., Cardellino CS., Allegra S., Bonifacio G., Cariti G., Di Perri G., D'Avolio A.
296Migraine and its chronicization to medication overuse headache: a pharmacoepidemiologic pharmacogenetic approach

Cargnin S., Terrazzino S., Da Cas R., Viana M., Sances G., Bianchi M., Ghiotto N., Tassorelli C., Nappi G., Canonico PL., Traversa G., Genazzani AA.
333Clinical validity and utility of DPYD polymorphisms: the present and the future of pharmacogenetic tests
Giodini L., Buonadonna A., Berretta M., De Paoli A., Scalone S., Miolo G., Mini E., Nobili S., Lonardi S., Pella N., Montico M., Roncato R., Dreussi E., Gagno S., Posocco B., Cecchin E., Toffoli G.
341miRNA-related SNPs as new predictive biomarkers of response to neo-adjuvant treatment in rectal cancer patients? An explorative analysis
Dreussi E., Polesel J., De Paoli A., Agostini M., Pucciarelli S., De Marchi F., Giodini L., Zanusso C., Gagno S., Roncato R., Toffoli G., Cecchin E.
359Genetic polymorphisms as a stratification factor that contributes to identify patients at high risk of developing Anthracycline-induced cardiomyopathy
Galli D., Fragni M., Ambrosiani L., Triggiani M., Cesana BM., Bonetti G., Cappellini S., Amoroso V., Simoncini EL., Berruti A., Spano P., Memo M., Nodari S., Sigala S.
93Altered antioxidant enzymatic and non enzymatic status in seminal plasma of men with different reproductive problems
Cerretani D., Micheli L., Collodel G., Menchiari A., Moltoni L., Moretti M., Fiaschi AI., Giorgi G.
737Detection Of IVS14+1G>A in Dihydropyrimidine Dehydrogenase Gene And 5-Fluorouracil Chemotherapy In Patients With Solid Malignancies
Vietri MT., Molinari AM., Capuano A., Caliendo G., Cenname A., Bernardi FF., Marabese I., Cioffi M., Rossi F.
78KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA
Del Re M., Tiseo M., D'Incecco A., Camerini A., Petrini I., Lucchesi M., Inno A., Spada D., Bordi P., Vasile E., Citi V., Malpeli G., Testa E., Gori S., Falcone A., Amoroso D., Chella A., Cappuzzo F., Ardizzoni A., Scarpa A., Danesi R.
80Detection of secondary mutations associated with drug resistance in circulating tumor DNA of patients with advanced ALK+ NSCLC
Belcari F., Bordi P., Del Re M., Citi V., Palombi M., Pinto C., Tiseo M., Danesi R.
83Automation of a throughput system for the diagnosis and the genotyping of Hepatitis C Virus
Zancan I., Renesto A., Paladin D., Giusti P.
165Oxidative stress parameters in serum of Hashimoto's thyroiditis patients
Vicchio TM., Certo R., Caccamo D., Certo G., Speciale A., Saija A., Gangemi S., Ruggeri RM., Cristani M., Centorrino F.
194Development and validation of a One-Step RT-Real Time PCR kit for detection and quantification of BCR-ABL p210
Gonzalez P., Costanzi G., Paladin D., Giusti P.
200The pharmacogenetics of tyrosine-kinase inhibitors in chronic myeloid leukemia: is there enough room for epigenetics?
Polillo M., Galimberti S., Crea F., Hsuan Liu H., Clermont PL., Guerrini F., Ciabatti E., Ricci F., Barate' C., Fontanelli G., Barsotti S., Morganti R., Wang Y., Petrini M., Helgason CD., Danesi R., Di Paolo A.
294Tamoxifen tailored treatment in breast cancer: splicing variants and pharmacogenetic profiles of ESR1 gene as new promising biomarkers
Bertolaso L., Pezzolo E., Pasini F., Gusella M.
332Pharmacokinetic analysis of weekly paclitaxel from patients enrolled in a genotype-driven phase I study: new horizon for conventional chemotherapeutic drugs
Posocco B., Marangon E., Giodini L., Scalone S., Sorio R., Toffoli G.
459Epicardial fat thickness is a marker of preclinical cardiovascular disease in the general population
Baragetti A., Pisano G., Garlaschelli K., Grigore L., Fracanzani AL., Fargion S., Norata GD., Catapano AL.
596Set-up experiments for microRNAs characterization in plasma and circulating tumor cells derived from patients with cutaneous melanoma
Polini B., Carpi S., Pardini B., Naccarati A., Romanini A., Fogli S., Nieri P.
645microRNAs as biomarkers of oxidant/antioxidant status
Balestra B., Lupo G., Paolini A., Pastoris O., Capelli E.
670Sex differences in metabolomic profile used for newborn screening

Ruoppolo M., Scolamiero E., Caterino M., Mirisola V., Franconi F., Campesi I.
696The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
Nassini R., Massi D., Brusa D., Merelli B., Falcone C., Xue G., Carobbio A., Baroni G., Tamborini E., Cattaneo L., Audrito V., Deaglio S., Mandalà M.